Kiniksa Pharmaceuticals Ltd   (KNSA)
Other Ticker:  
Price: $20.1600 $0.16 0.800%
Day's High: $20.22 Week Perf: 1.2 %
Day's Low: $ 19.84 30 Day Perf: 9.86 %
Volume (M): 251 52 Wk High: $ 20.94
Volume (M$): $ 5,054 52 Wk Avg: $15.72
Open: $20.00 52 Wk Low: $10.29

 Market Capitalization (Millions $) 1,415
 Shares Outstanding (Millions) 70
 Employees 186
 Revenues (TTM) (Millions $) 249
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -58
 Capital Exp. (TTM) (Millions $) 0

Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for patients with devastating diseases and unmet medical needs. The company was founded in 2015 and is based in Hamilton, Bermuda.

The company has a portfolio of product candidates targeting multiple indications, including autoimmunity, inflammation, and oncology. These product candidates are based on the company's expertise in immune and inflammatory pathways.

Kiniksa's lead product candidate is Rilonacept, a recombinant fusion protein that blocks interleukin-1 alpha and beta, which are cytokines that play a significant role in inflammation. Rilonacept is currently in Phase III clinical trials for the treatment of recurrent pericarditis, a rare autoinflammatory disease affecting the lining of the heart.

The company's other product candidates include KPL-716, a monoclonal antibody that targets the CD40 ligand, which is a critical mediator of inflammation in multiple autoimmune diseases. KPL-404 is another product candidate being developed for the treatment of prurigo nodularis, a chronic itch disorder.

Kiniksa Pharmaceuticals operates with a focus on research and development, seeking out new methodologies to develop new therapeutics. This includes collaborating with various research institutions and universities, as well as partnering with other biotechnology and pharmaceutical companies.

The company's management team consists of industry veterans with extensive experience in drug discovery, development, and commercialization. Furthermore, the company follows a well-defined set of values and principles, promoting ethical behavior and corporate social responsibility.

In summary, Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company that is committed to discovering and developing therapeutics for patients with unmet medical needs. With a strong pipeline of product candidates and a focus on research and development, the company has positioned itself as a leader in the biotechnology industry. Additionally, the company operates with a strong sense of corporate social responsibility, promoting ethical behavior and transparency in its operations.

   Company Address: Clarendon House Hamilton 0
   Company Phone Number: 451-3453   Stock Exchange / Ticker: NASDAQ KNSA
   KNSA is expected to report next financial results on March 01, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Kiniksa Pharmaceuticals: A revenue rocket launching with ARCALYST's Impressive 90% YoY surge.

Published Thu, Jan 4 2024 12:30 PM UTC

Kiniksa Pharmaceuticals has announced yet another remarkable milestone in its Q4 financial report. A key highlight of this announcement is the firm's impressive growth surge for its product ARCALYST (rilonacept), which witnessed an approximately 90% leap in net product revenue year-over-year to a staggering $233.1 million, a figure that remains unaudited.ARCALYST, a well-kno...

Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd Shocks Investors with a Staggering -32.369% Drop in Revenue for Recent Fiscal Period

During the past 5 trading days, Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) stock has experienced no change, bringing its year-to-date performance to 5.61%. Currently trading on the NASDAQ, the stock is 3.5% above its 52-week average.
However, recent financial reports indicate a disappointing fiscal period for this major pharmaceutical preparations company. In the period ending September 30, 2023, Kiniksa Pharmaceuticals Ltd reported a significant decline in revenue of -32.369%, amounting to $67.05 million. The company also posted a net loss per share of -$0.20, compared to $3.18 in the third quarter of 2022.

Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Soars with Stellar 164.99% YoY Revenue Increase, Boosted by $16.21M Tax Provisions

Kiniksa Pharmaceuticals Ltd, a leading company in the Major Pharmaceutical Preparations industry, has reported astonishing revenue growth of 164.99% year on year, reaching $71.47 million in the second quarter of 2023. This positive development has resulted in the company turning a profit, with earnings per share (EPS) at $0.21.
Compared to its industry peers, Kiniksa Pharmaceuticals Ltd has outperformed, as the average revenue growth for Major Pharmaceutical Preparations companies during the same period was only 3.78%. Moreover, this impressive result is a significant improvement from the previous financial period, where earnings per share stood at -$0.18 and the company recorded a 47.839% surge in revenue from $48.35 million.

Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd outperforms expectations with an impressive ROI of 56.52% in Q1 2023

Investors in Kiniksa Pharmaceuticals Ltd can take solace in the fact that the company achieved a return on average invested assets (ROI) of 56.52% in its first quarter of 2023. While this is a slight dip from the company's average ROI of 61.41%, it is still an impressive performance in the challenging Healthcare sector.
What's more, despite a decrease in net income that led to the decline in ROI relative to the previous quarter, Kiniksa Pharmaceuticals Ltd's ROI ranking has improved from 116 in the fourth quarter of 2022 to 66 in the March 31, 2023 quarter. This indicates the company's firm financial footing and its significant potential for growth.


Kiniksa Pharmaceuticals Ltd's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com